Ocular Therapeutix, Inc.
OCUL
$11.36
$0.110.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.21% | -7.26% | -0.33% | 9.03% | 6.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.21% | -7.26% | -0.33% | 9.03% | 6.45% |
| Cost of Revenue | 78.13% | 105.98% | 114.42% | 100.89% | 71.57% |
| Gross Profit | -191.87% | -379.37% | -659.67% | -780.91% | -743.44% |
| SG&A Expenses | 47.85% | 49.03% | 43.06% | 43.17% | 12.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.81% | 78.52% | 77.22% | 70.36% | 39.16% |
| Operating Income | -99.11% | -128.07% | -127.97% | -113.86% | -62.26% |
| Income Before Tax | -43.21% | -56.65% | -67.19% | -139.68% | -159.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.21% | -56.65% | -67.19% | -139.68% | -159.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.21% | -56.65% | -67.19% | -139.68% | -159.98% |
| EBIT | -99.11% | -128.07% | -127.97% | -113.86% | -62.26% |
| EBITDA | -101.85% | -132.56% | -132.46% | -117.12% | -62.62% |
| EPS Basic | -8.83% | -15.32% | -3.59% | -25.00% | -52.56% |
| Normalized Basic EPS | -43.47% | -32.60% | -9.13% | 9.48% | -1.13% |
| EPS Diluted | -9.05% | 5.44% | 15.02% | -0.56% | -15.20% |
| Normalized Diluted EPS | -43.47% | -34.24% | -10.41% | 8.52% | -3.77% |
| Average Basic Shares Outstanding | 26.34% | 46.65% | 79.27% | 98.24% | 76.15% |
| Average Diluted Shares Outstanding | 26.34% | 44.84% | 76.54% | 94.72% | 69.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |